



Qty: 100 µg/400 µl

Rabbit anti-ALK

Catalog No. 51-3900

Lot No. See product label

## Rabbit anti-ALK

### FORM

Liquid. This polyclonal antibody is supplied as a 400 µL aliquot at a concentration of 0.25 mg/ml in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. The antibody is epitope-affinity-purified from rabbit antiserum.

**PAD (Polyclonal Antibody Designation):** ZAL4

### IMMUNOGEN

A recombinant protein derived from amino acids 1359-1466 of the 1620 amino acid human ALK protein which corresponds to amino acids 426-528 of the 680 NPM-ALK chimeric protein.

### SPECIFICITY

This antibody reacts specifically with the 1620 amino acid ALK protein, detecting a band of approximately 80,000 Mr on Western blots. Cross-reactivity with related proteins has not been observed.

### REACTIVITY

Reactivity of this antibody with ALK was confirmed by Western blotting and immunohistochemistry with human T-cell lines harbouring the NPM-ALK translocation, including Karpas 299, DHL, and TS cells. Cell lines testing negative include Jurkat, and the B-cell lines BL60, IARC, Ramos, and Raji. Reactivity with other species has not been tested.

Sample	ELISA	Immunohistochemistry (paraffin or frozen)	Western Blotting
Human		+	+
Immunogen	+		

### USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The following concentration ranges are recommended starting points for this product.

**ELISA:** 0.1-1.0 µg/ml  
**Immunohistochemistry:** 5-10 µg/ml  
**Western Blotting:** 1-5 µg/ml

The suitability of this antibody for applications other than those mentioned here has not been evaluated.

### STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.

(cont'd)

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

PI513900

(Rev 10/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

(51-3900 cont'd)

## BACKGROUND

Anaplastic large-cell lymphoma (ALCL), an aggressive subtype of non-Hodgkin's lymphoma, is characterized by CD30<sup>+</sup> large neoplastic cells and frequently contains the (2:5)(p23:g35) translocation.<sup>(1)</sup> The (2:5) translocation results in the production of a chimeric 80 kDa protein, NPM-ALK (Nucleophosmin-Anaplastic lymphoma Kinase) or p80. However, ALK has also been found in cases of large B-cell lymphomas that lack the t(2:5).<sup>(2)</sup> The ALK<sup>+</sup> subset of ALCL have been studied in several recent papers.<sup>(3-10)</sup> It has been proposed that ALK<sup>+</sup> ALCL is a separate clinicopathologic entity, ALK lymphoma, that is distinct from ALK-ALCL.<sup>(6,7,9)</sup> Significantly, it has been reported that ALK lymphoma has a different prognosis than ALK-ALCL.<sup>(8-10)</sup>

## REFERENCES

1. Morris, S. W. et al; Oncogene 14:2175 (1997).
2. Delsol, G. et al; Blood 89:1483-1490 (1997).
3. Pulford, K. et al; Am J Pathol. 154:1657-1663 (1999).
4. Kinney, M.C. and Kadin, M.E., Am J Clin Pathol 111 (Suppl 1) S56-67 (1999).
5. Chan, J. K. Adv Anat Pathol 5: 281-313 (1998).
6. Benharroch, D. et al; Blood 91 (6): 2076-2084 (1998).
7. Falini, B. et al; Am. J Pathol 153(3):875-886 (1998).
8. Falini, B. et al; Blood 93(8):2697-2706 (1999).
9. Shioto, M. et al; Blood 86(5): 1954-1960 (1995).
10. Gascoyne, R.D., et al; Blood 93:3913-3921 (1999).

## RELATED PRODUCTS

<b>Product</b>	<b>Form</b>	<b>PAD/Clone</b>	<b>Cat. No.</b>
Rb x ALK	Purified (vs. aa 428-685)	ZAL8	51-4000
Ms x CD30 (Ki-1)	Predilute for Histology	Ber-H2	08-0155
Ms x CD30 (Ki-1)	2 <sup>nd</sup> Gen Predilute for Histology	Ber-H2	08-1155

*PAD: Polyclonal antibody designation*

<b>Product</b>	<b>Conjugate</b>	<b>Cat. No.</b>
Goat x Rabbit IgG (H+L) (ZyMAX™ Grade)	Purified	81-6100
	FITC	81-6111
	TRITC	81-6114
	Cy™3	81-6115
	Cy™5	81-6116
	HRP	81-6120
	AP	81-6122
	Biotin	81-6140
Protein A	Sepharose® 4B	10-1041
rec-Protein G	Sepharose® 4B	10-1241

Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™3 and Cy™5 are trademarks of Amersham Life Sciences, Inc. Sepharose® is a registered trademark of Pharmacia LKB.

**For Research Use Only**

MC020712

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

PI513900

(Rev 10/08) DCC-08-1089

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.